Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

: China has implemented universal hepatitis B vaccination since 2002 and provided charge-free hepatitis B immunoglobulin (HBIG) to infants of HBV-infected mothers since July 2011. We aimed to compare mother-to-child transmission (MTCT) in children born before and since July 2011.: In total, 5,149 children of HBV-infected mothers were tested for HBV markers. Group one contained 1,160 children born during August 2002-June 2011 and group two contained 3,989 children born during July 2011-June 2016.: In total, 92 (1.8%, 95% confidence interval [95%CI] 1.4-2.2) children were infected with HBV. None (0%, 95%CI 0.0-0.1) of 3,716 children of mothers with negative hepatitis B e antigen (HBeAg) was infected, whereas 92 (6.4%, 95%CI 5.2-7.8) of 1,433 children of HBeAg-positive mothers were infected (p < 0.0001). Among children of HBeAg-positive mothers, MTCT occurred in 10.3% (19/185) (95%CI 6.3-15.6) in group one and 5.8% (73/1,248) (95%CI 4.6-7.3) in group two (p = 0.02).: Implementing charge-free active-passive immunoprophylaxis greatly reduces MTCT of HBV in children of HBeAg-positive mothers, highlighting the importance of timely administration of both hepatitis B vaccine and HBIG to prevent MTCT. The still remaining MTCT suggests that reducing maternal virus load before delivery is an additional important measure.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2021.1927723DOI Listing

Publication Analysis

Top Keywords

children born
12
mother-to-child transmission
8
hbv-infected mothers
8
july 2011
8
born july
8
group contained
8
children
7
reduced mother-to-child
4
hepatitis
4
transmission hepatitis
4

Similar Publications

Importance: Neonatal intensive care has advanced over recent decades, yet premature birth remains associated with increased neonatal mortality and morbidity.

Objective: To describe health service use, morbidity, and medication needs up to age 5 years in a contemporary cohort of children born preterm.

Design, Setting, And Participants: This population-based cohort study was conducted in British Columbia (BC), Canada, using health service and pharmacy data linked using provincial administrative databases.

View Article and Find Full Text PDF

Background: Adverse reproductive outcomes (AROs) in women can lead to the occurrence of a variety of diseases later in life. However, research on AROs and dementia risk in women has not been reported.

Objective: This study explored the effects of miscarriage and stillbirth on future dementia risk in women.

View Article and Find Full Text PDF

Clotting factor concentrate (CFC), used to treat and prevent bleeding in hemophilia, is rendered ineffective if clotting factor neutralizing antibodies (inhibitors) develop. Inhibitors occur most often in children, early in treatment. The American Thrombosis and Hemostasis Network (ATHN) 8: US Cohort Study of Previously Untreated Patients (PUPs) with Congenital Hemophilia, conducted in children born in 2010 to 2020 with severe or moderate hemophilia, was designed to determine the percentage of participants who developed a confirmed, clinically significant inhibitor within the first 50 CFC exposure days (EDs).

View Article and Find Full Text PDF

In 2009, the World Health Organization called for global universal birth dose hepatitis B virus (HBV) vaccination; however, in Canada, five provinces still vaccinate adolescents. The National Advisory Committee on Immunization (NACI) recommends province-to-province assessment of local epidemiology and states that if there is a failure of the routine immunization program, as indicated by HBV infection occurring in infants and children awaiting vaccination, that changes should be made. It has now been shown in Ontario that children under the age of 12 who are born in Canada are acquiring HBV prior to adolescent vaccination.

View Article and Find Full Text PDF

In the last decade, hepatitis C virus (HCV) has become a curable chronic viral infection, with excellent treatment and streamlined diagnostic testing. Canada and many other countries have adopted national elimination targets; however, reaching these goals will require changes in the way care is provided. Standard of care HCV treatment is all-oral daily medication for 8 or 12 weeks and all provinces in Canada have mechanisms for public coverage.

View Article and Find Full Text PDF